Results 51 to 60 of about 6,004 (159)
IJU Case Reports, Volume 9, Issue 2, March 2026.ABSTRACT Introduction Pituitary apoplexy represents an uncommon endocrine emergency with potentially life‐threatening consequences. Gonadotropin‐releasing hormone agonist used for prostate cancer has the potential to induce pituitary apoplexy, particularly in the setting of a preexisting pituitary adenoma.
Masaaki Fujimura +5 more
wiley +1 more source
A Case of Leuprolide-Induced Posterior Reversible Encephalopathy Syndrome [PDF]
Journal of Neurocritical Care, 2016 Background Leuprolide is a gonadotropin releasing hormone agonist used for patients with prostate cancer and a variety of gynecologic diseases, such as uterine myoma, endometriosis, and adenomyosis.
Chae Young Lee +5 more
doaj +1 more source
MedComm, Volume 7, Issue 3, March 2026.HS1002, a new peptide targeting GnRHR and hTERT, demonstrates significant Anticancer activity in prostate cancer cells. The mechanism of HS1002 can be attributed to the reduction of serum testosterone levels by desensitization of GnRHR, the downregulation of hTERT expression and telomerase activity, and the enhancement of Anticancer immunity.
Jae Hyeon Park +6 more
wiley +1 more source
Gonadotropin releasing hormone agonists: Expanding vistas
Indian Journal of Endocrinology and Metabolism, 2011 Gonadotropin-releasing hormone (GnRH) agonists are derived from native GnRH by amino acid substitution which yields the agonist resistant to degradation and increases its half-life.
Navneet Magon
doaj +1 more source
Nanochanneled Device and Related Methods [PDF]
, 2013 A nanochannel delivery device and method of manufacturing and use. The nanochannel delivery device comprises an inlet, an outlet, and a nanochannel. The nanochannel may be oriented parallel to the primary plane of the nanochannel delivery device.
Ferrari, Mauro +7 more
core +2 more sources
Considerations for Menstrual Suppression in Patients With Hematologic Malignancies
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 3, March 2026.ABSTRACT Patients who menstruate during treatment for hematologic malignancies have a higher risk of heavy vaginal bleeding due to thrombocytopenia caused by malignancy and myelosuppressive chemotherapy. Heavy menstrual bleeding is associated with significant morbidity in this patient population, and menstrual suppression is a standard of supportive ...
Sahaana Veeravalli +3 more
wiley +1 more source
Artificial lipidation of proteins and peptides: from mechanism to clinical applications
The FEBS Journal, Volume 293, Issue 5, Page 1269-1284, March 2026.Artificial lipidation transforms protein and peptide therapeutics by attaching fatty acid chains through reversible or permanent chemical strategies. This biomimetic approach delivers four key therapeutic advantages: extended circulation times (enabling weekly instead of daily dosing), alternative administration routes including oral delivery, precise ...
Jiaming Mu, Emily Vong, Sheiliza Carmali
wiley +1 more source
Central precocious puberty: From genetics to treatment [PDF]
, 2018 Central precocious puberty (CPP) results from early activation of the hypothalamic - pituitary -gonadal (HPG) axis and follows the same sequence as normal puberty.
Eugster, Erica A. +1 more
core +1 more source
Journal of Clinical Nursing, Volume 35, Issue 3, Page 1234-1243, March 2026.ABSTRACT Aim To explore challenges parents of children with cancer encounter while providing complex medical care at home. Methods Design: Cross‐sectional convergent mixed‐methods study. Instruments: Questionnaire and open interviews that mirrored and complemented each other.
Rachel Klausner Shyman +5 more
wiley +1 more source
Acta Chimica SlovenicaLeuprolide acetate is a synthetic gonadotropin-releasing hormone agonist used in the treatment of central precocious puberty, uterine fibroids, endometriosis, and prostate cancer. In this study, the rapid, simple, environmentally friendly, and sensitive
Begüm Evranos Aksöz, Burcu Dogan-Topal
doaj +1 more source